Genmab A/S announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy treatment for adult ...

Pfizer acquired Seagen in December 2023. Tivdak comprises Genmab’s human monoclonal antibody directed to tissue factor (TF) with the ADC technology of Pfizer, which leverages a protease ...

Pfizer acquired Seagen in December 2023. Tivdak comprises Genmab’s human monoclonal antibody directed to tissue factor (TF) with the ADC technology of Pfizer, which leverages a protease-cleavable ...

Japan approves Tivdak, the first ADC for cervical cancer, after Phase 3 trial shows a 30% reduction in death risk vs. chemotherapy. The trial of 502 patients showed Tivdak improved median overall ...

The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ (NASDAQ:GMAB) Tivdak (tisotumab vedotin) for advanced or recurrent cervical cancer that has progressed on or after ...

(RTTNews) - Genmab A/S (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved TIVDAK for the treatment of advanced or recurrent cervical cancer that has progressed on ...

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved Tivdak for the treatment of advanced or recurrent cervical cancer that has progressed on or after cancer ...

Tivdak is the first and only ADC to be approved for people living with cervical cancer in Japan, noted Genmab, whose shares rose 3.2% to 1,399 kroner on the news. The drug was developed by Seagen, now ...

Tivdak, which Pfizer acquired through its acquisition of Seagen in December 2023, is the first ADC to have positive overall survival data for patients with previously treated recurrent or ...

Boehringer Ingelheim (BI) and Salipro Biotech have entered into a partnership aimed at accelerating the development of multiple drug targets. The research and licence agreement will focus on advancing ...

Genmab (GMAB) announced updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan, an investigational folate receptor-alpha-targeted, TOPO1 antibody-drug conjugate that ...